- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/725 - Récepteurs de lymphocytes-T
Détention brevets de la classe C07K 14/725
Brevets de cette classe: 8780
Historique des publications depuis 10 ans
|
405
|
511
|
717
|
832
|
1020
|
1192
|
986
|
880
|
797
|
422
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Immatics Biotechnologies GmbH | 1126 |
550 |
| The Trustees of the University of Pennsylvania | 4435 |
251 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3016 |
231 |
| The Regents of the University of California | 20868 |
157 |
| Memorial Sloan-Kettering Cancer Center | 2058 |
148 |
| Autolus Limited | 271 |
128 |
| Board of Regents, The University of Texas System | 6161 |
118 |
| Novartis AG | 10174 |
110 |
| Regeneron Pharmaceuticals, Inc. | 4800 |
109 |
| Juno Therapeutics, Inc. | 503 |
103 |
| Immunocore Limited | 245 |
98 |
| Cellectis | 415 |
91 |
| Kite Pharma, Inc. | 457 |
89 |
| City of Hope | 1047 |
87 |
| Lentigen Technology, Inc. | 108 |
80 |
| CRISPR Therapeutics AG | 372 |
78 |
| Fred Hutchinson Cancer Center | 485 |
73 |
| The Board of Trustees of the Leland Stanford Junior University | 6707 |
67 |
| The General Hospital Corporation | 4881 |
57 |
| Adaptimmune Limited | 143 |
55 |
| Autres propriétaires | 6100 |